CNS Pharma raises $3.7M in $0.30/unit offering; appoints Amy Mahery to board

CNS Pharmaceuticals, Inc.

Offering of 2.2M shares, 11.1M pre-funded warrants, and 26.7M Series A & B warrants at $0.30 per unit.
Gross proceeds ~$3.7M; net proceeds to fund CNS-201 trial and working capital.
Amy Mahery appointed independent director as of Feb 1, 2024; Andrzej Andraczke resigned.
Warrant amendment for 3.756M existing warrants: exercise price reduced to $0.30 if shareholder approved.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Amy Mahery

Independent Director

CNSP · CNS Pharmaceuticals, Inc.

Filed: February 2, 2024, 6:59 PM ET

As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Mahery was appointed as Independent Director at CNS Pharmaceuticals, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC valued at $3.7 million (effective 2024-01-29).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners and Maxim Group LLC
Value: $3.7 million
Effective: 2024-01-29

Exact text from the filing

On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”) and Maxim Group LLC (“Maxim” and collectively with AGP, the “Placement Agents”) (the “Placement Agreement”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CNS Pharmaceuticals, Inc. amended Warrant Amendment (effective 2024-01-29).

Action: amendment
Effective: 2024-01-29

Exact text from the filing

anuary 29, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment”) pursuant to which the Company

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2024-01-29).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2024-01-29

Exact text from the filing

the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors that participated in the offering

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-000660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.